# Replacement of nitro function by free boronic acid in the group of non-steroidal anti-androgens.

Petr Šlechta<sup>1</sup>, Roman Viták<sup>2</sup>, Pavel Bárta<sup>3</sup>, Kateřina Koucká<sup>1</sup>, Monika Berková<sup>1</sup>, Diana Žďárová<sup>1</sup>, Andrea Petríková<sup>1</sup>, Jiří Kuneš<sup>4</sup>, Vladimír Kubíček<sup>3</sup>, Martin Doležal<sup>1</sup>, Radek Kučera<sup>2</sup>, and Marta Kučerová-Chlupáčová<sup>1\*</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203/8, 50003 Hradec Králové, Czech Republic

<sup>2</sup> Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, 32300 Plzeň, Czech Republic

<sup>3</sup> Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203/8, 50003 Hradec Králové, Czech Republic

<sup>4</sup> Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203/8, 50003 Hradec Králové, Czech Republic

\*Email: kucerom@faf.cuni.cz

## Supporting information

#### Table of contents

Results of in vitro cytotoxicity screening	S1
Table S1	S1
Table S2	S4
Table S3	S5
Table S4	S5
NMR spectra of final compounds	S6

#### Results of in vitro cytotoxicity screening

Table S1: Complete results of in vitro cytotoxicity screening for aromatic amides against the tested cell lines with indicated incubation time and calculated selectivity index (SI).

		IC <sub>50</sub> (μM)					
Structure	Code	HepG2	PC3	PC3	HK-2	LAPC4	SI (HK-
		(24 h)	(24 h)	(72 h)	(72 h)	(72 h)	2/LAPC4)
	1a	>250	>100	na	na	>100	na
OH N H <sub>3</sub> C N N H	2a	>100	>100	na	na	>100	na
OH N H N CH <sub>3</sub>	3a	>500	>1000	na	na	>100	na

	4a	>500	>250	na	na	>100	na
	5a	139.3	133.4	121.6	194.5	27.8	7.0
OH N N N N N N N N N N N N N N N	6a	>250	>250	na	na	>100	na
	7a	>500	>500	na	na	>100	na
	8a	126.4	193.3	375.2 422.4		78.3	5.4
	9a	71.26	118.4	78.1	137.7	19.2	7.2
CI N H BOH	10a	187	>1000	227.9	183.7	48.0	3.8
	<b>11</b> a	>1000	296	779.6	1000	>100	na
	12a	>1000	na	na	na	>100	na
OH N H BOH	<b>13</b> a	>250	>250	na	na	>100	na
F <sub>3</sub> C N H H H H	14a	>100	>100	na	na	>100	na
F <sub>3</sub> C N H H OH	<b>15</b> a	>25	>50	na	na	>100	na

	<b>1</b> 6a	>50	>50	na	na	>100	na
OH OH BOH	17a	>25	>100	na	na	>100	na
OH N N H OH B OH	<b>18</b> a	>50	>50	na	na	>100	na
	19a	>50	>50	na	na	>100	na
	20a	322.2	>250	na	na	>100	na

NOTE: na= not available.

Table S2: Complete results of in vitro cytotoxicity screening for aliphatic and alicyclic amides against the tested cell lines with indicated incubation time and calculated selectivity index (SI).

		IC <sub>so</sub> (μM)					
Structure	Code	HepG2	PC3	PC3	HK-2	LAPC4	SI (HK-
		(24 h)	(24 h)	(72 h)	(72 h)	(72 h)	2/LAPC4)
HN-C-B,OH F	1b	>1000	>1000	na	na	>100	na
HN-C-B HN-F OH	2b	>1000	>1000	na	na	>100	na
HN - B OH F OH	3b	>1000	877.7	na	na	>100	na
HN HN F	4b	>250	>250	na	na	>100	na
OH N H H H H	5b	>250	>250	na	na	>100	na
OH BOH F	6b	>1000	>1000	na	na	>100	na
OH BOH F	7b	>500	>1000	na	na	>100	na

NOTE: na= not available.

Table S3: Complete results of in vitro cytotoxicity screening for aliphatic and alicyclic amides substituted with trifluoromethyl group against the tested cell lines with indicated incubation time and calculated selectivity index (SI).

		IC <sub>50</sub> (μM)						
Structure	Code	HepG2 PC3 PC3		HK-2	LAPC4	SI (HK-		
		(24h)	(24h)	(72h)	(72h)	(72h)	2/LAPC4)	
HO H B OH CF3	HFB	>1000	>1000	>1000	>1000	403.8	na	
OH N CF <sub>3</sub>	1c	>1000	>1000	697.1	>1000	>100	na	
HN HN CF <sub>3</sub> OH	2c	>1000	>1000	na	na	>100	na	
O HN CF <sub>3</sub> OH	Зc	>1000	>500	na	na	>100	na	
OH BOH CF3	4c	>1000	>1000	na	na	>100	na	
OH BOH CF3	5c	>1000	>1000	185.6	>1000	>100	na	

NOTE: na= not available.

Table S4: Results of in vitro cytotoxicity screening for standards against the tested cell lines with indicated incubation time and calculated selectivity index (SI).

Structure	Code	IC <sub>50</sub> (μM)							
		HepG2	PC3	PC3	HK-2	LAPC4	SI (HK-		
		(24 h)	(24 h)	(72 h)	(72 h)	(72 h)	2/LAPC4)		
N <sup>+</sup> O <sup>-</sup> H CF <sub>3</sub>	flutamide	137.2	34.7	50.8	76.2	60.5	1.3		
	HF	103.2	229.2	41.8	231.0	136.1	1.7		
HN HN CF <sub>3</sub> HO O O F	bicalutamide (racemic mixture)	na	na	na	na	37.2	na		

NOTE: na= not available.

## NMR spectra of final compounds HFB <sup>1</sup>H NMR spectrum





#### HFB <sup>11</sup>B NMR spectrum



































8a <sup>1</sup>H NMR spectrum





#### 9a <sup>1</sup>H NMR spectrum







2.50 DMSO-D6 2.49 DMSO-D6 2.49 DMSO-D6 2.49 DMSO-D6 10a - 0.28 4.50  $\overbrace{\substack{9.49\\9.47\\9.01\\8.87}}^{9.49}$ 0 - 0.26 - 0.24 ОН сſ -0.22 I OH -0.20 -0.18 B (m) 9.01 E (d) 7.72 -0.16 D (s) F (d) 7.95 7.27 G (d) 4.49 A (t) 9.48 -0.14 C (s) 8.87 -0.12 -0.10 - 0.08 - 0.06 -0.04 - 0.02 - 0.00 2.07 F-00.1 1.91-T 1.89-T 1.89-T - -0.02 7 f1 (ppm) 15 13 11 10 9 8 3 0 -1 14 12 6 5 4 2 1























#### 15a <sup>1</sup>H NMR spectrum

















18a <sup>1</sup>H NMR spectrum 18a ---- 3.36 H2O - 10.80 49 400 ŅН - 350 0 NH - 300 F (d) 7.91 - 250 D (m) 8.21 B (s) 9.54 C (m) 8.29 A (s) 10.80 - 200 E (s) 8.00 - 150 G (d) 7.83 - 100 - 50 - 0 0.98 0.95 3.49 1.88 1.94 **--------------**0.97----0.78-= 6 f1 (ppm) 3 13 12 11 10 9 4 2 1 0 -1 8 5 7



#### 19a <sup>1</sup>H NMR spectrum





## 19<sup>11</sup>B NMR spectrum







#### 1b<sup>1</sup>H NMR spectrum













#### 3b <sup>1</sup>H NMR spectrum



S40

#### 3b <sup>11</sup>B NMR spectrum



#### 4b<sup>1</sup>H NMR spectrum









## 5b <sup>11</sup>B NMR spectrum









#### 7b<sup>11</sup>B NMR spectrum



#### 1c<sup>1</sup>H NMR spectrum





#### 2c<sup>1</sup>H NMR spectrum



## 2c<sup>11</sup>B NMR spectrum









### 4c <sup>1</sup>H NMR spectrum





#### 4c<sup>11</sup>B NMR spectrum



#### 5c<sup>1</sup>H NMR spectrum



